Buchumschlag

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy: EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy— EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Roeper, Julia (VerfasserIn) , Christopoulos, Petros (VerfasserIn) , Falk, Markus (VerfasserIn) , Heukamp, Lukas (VerfasserIn) , Tiemann, Markus (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Thomas, Michael (VerfasserIn) , Griesinger, Frank (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 2022
In: Translational Lung Cancer Research
Year: 2022, Jahrgang: 11, Heft: 1, Pages: 4-16
ISSN:2226-4477
DOI:10.21037/tlcr-21-754
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.21037/tlcr-21-754
Verlag, lizenzpflichtig, Volltext: https://tlcr.amegroups.com/article/view/60522
Resolving-System, kostenfrei: https://doi.org/10.21037/tlcr-21-754
Volltext
Verfasserangaben:Julia Roeper, Petros Christopoulos, Markus Falk, Lukas C. Heukamp, Markus Tiemann, Albrecht Stenzinger, Michael Thomas, Frank Griesinger

MARC

LEADER 00000caa a2200000 c 4500
001 1789524261
003 DE-627
005 20220820130338.0
007 cr uuu---uuuuu
008 220214s2022 xx |||||o 00| ||eng c
024 7 |a 10.21037/tlcr-21-754  |2 doi 
035 |a (DE-627)1789524261 
035 |a (DE-599)KXP1789524261 
035 |a (OCoLC)1341441734 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Roeper, Julia  |d 1982-  |e VerfasserIn  |0 (DE-588)1187846279  |0 (DE-627)1666823643  |4 aut 
245 1 0 |a TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy  |b EGFR mutated non-small cell lung cancer IV patients treated with osimertinib  |c Julia Roeper, Petros Christopoulos, Markus Falk, Lukas C. Heukamp, Markus Tiemann, Albrecht Stenzinger, Michael Thomas, Frank Griesinger 
264 1 |c January 2022 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 14.02.2022 
520 |a TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy— EGFR mutated non-small cell lung cancer IV patients treated with osimertinib 
700 1 |a Christopoulos, Petros  |d 1977-  |e VerfasserIn  |0 (DE-588)138659702  |0 (DE-627)604886756  |0 (DE-576)308488067  |4 aut 
700 1 |a Falk, Markus  |d 1974-  |e VerfasserIn  |0 (DE-588)129929158  |0 (DE-627)707352061  |0 (DE-576)297907522  |4 aut 
700 1 |a Heukamp, Lukas  |e VerfasserIn  |0 (DE-588)1225306612  |0 (DE-627)174487266X  |4 aut 
700 1 |a Tiemann, Markus  |e VerfasserIn  |0 (DE-588)1235726401  |0 (DE-627)1760770388  |4 aut 
700 1 |a Stenzinger, Albrecht  |e VerfasserIn  |0 (DE-588)139606106  |0 (DE-627)703395238  |0 (DE-576)312432755  |4 aut 
700 1 |a Thomas, Michael  |e VerfasserIn  |0 (DE-588)1054438781  |0 (DE-627)79152213X  |0 (DE-576)41027089X  |4 aut 
700 1 |a Griesinger, Frank  |e VerfasserIn  |0 (DE-588)1080408916  |0 (DE-627)844436305  |0 (DE-576)453541747  |4 aut 
773 0 8 |i Enthalten in  |t Translational Lung Cancer Research  |d [Erscheinungsort nicht ermittelbar] : [Verlag nicht ermittelbar], 2012  |g 11(2022), 1, Seite 4-16  |h Online-Ressource  |w (DE-627)777778599  |w (DE-600)2754335-3  |w (DE-576)400525224  |x 2226-4477  |7 nnas  |a TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy EGFR mutated non-small cell lung cancer IV patients treated with osimertinib 
773 1 8 |g volume:11  |g year:2022  |g number:1  |g pages:4-16  |g extent:13  |a TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy EGFR mutated non-small cell lung cancer IV patients treated with osimertinib 
856 4 0 |u https://doi.org/10.21037/tlcr-21-754  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://tlcr.amegroups.com/article/view/60522  |x Verlag  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://doi.org/10.21037/tlcr-21-754  |x Resolving-System  |z kostenfrei 
951 |a AR 
992 |a 20220214 
993 |a Article 
994 |a 2022 
998 |g 1054438781  |a Thomas, Michael  |m 1054438781:Thomas, Michael  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PT1054438781  |e 950000PT1054438781  |e 950900PT1054438781  |e 50000PT1054438781  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 7 
998 |g 139606106  |a Stenzinger, Albrecht  |m 139606106:Stenzinger, Albrecht  |d 910000  |d 912000  |e 910000PS139606106  |e 912000PS139606106  |k 0/910000/  |k 1/910000/912000/  |p 6 
998 |g 138659702  |a Christopoulos, Petros  |m 138659702:Christopoulos, Petros  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PC138659702  |e 950000PC138659702  |e 950900PC138659702  |e 50000PC138659702  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 2 
999 |a KXP-PPN1789524261  |e 4056432619 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1789524261","relHost":[{"disp":"TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy EGFR mutated non-small cell lung cancer IV patients treated with osimertinibTranslational Lung Cancer Research","titleAlt":[{"title":"Transl Lung Cancer Res"},{"title":"TLCR"}],"part":{"volume":"11","issue":"1","text":"11(2022), 1, Seite 4-16","extent":"13","pages":"4-16","year":"2022"},"pubHistory":["1.2012 -"],"recId":"777778599","title":[{"title":"Translational Lung Cancer Research","subtitle":"TLCR","title_sort":"Translational Lung Cancer Research"}],"note":["Gesehen am 03.12.2021"],"language":["eng"],"origin":[{"dateIssuedDisp":"2012-","publisher":"[Verlag nicht ermittelbar]","dateIssuedKey":"2012","publisherPlace":"[Erscheinungsort nicht ermittelbar]"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2754335-3"],"eki":["777778599"],"issn":["2226-4477"]},"name":{"displayForm":["Society for Translational Cancer Research (STCR)"]}}],"title":[{"title":"TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy","title_sort":"TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy","subtitle":"EGFR mutated non-small cell lung cancer IV patients treated with osimertinib"}],"note":["Gesehen am 14.02.2022"],"language":["eng"],"person":[{"display":"Roeper, Julia","family":"Roeper","role":"aut","given":"Julia"},{"given":"Petros","role":"aut","family":"Christopoulos","display":"Christopoulos, Petros"},{"role":"aut","given":"Markus","display":"Falk, Markus","family":"Falk"},{"role":"aut","given":"Lukas","display":"Heukamp, Lukas","family":"Heukamp"},{"family":"Tiemann","display":"Tiemann, Markus","given":"Markus","role":"aut"},{"role":"aut","given":"Albrecht","display":"Stenzinger, Albrecht","family":"Stenzinger"},{"given":"Michael","role":"aut","family":"Thomas","display":"Thomas, Michael"},{"given":"Frank","role":"aut","family":"Griesinger","display":"Griesinger, Frank"}],"physDesc":[{"extent":"13 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Julia Roeper, Petros Christopoulos, Markus Falk, Lukas C. Heukamp, Markus Tiemann, Albrecht Stenzinger, Michael Thomas, Frank Griesinger"]},"id":{"doi":["10.21037/tlcr-21-754"],"eki":["1789524261"]},"origin":[{"dateIssuedDisp":"January 2022","dateIssuedKey":"2022"}]} 
SRT |a ROEPERJULITP53COMUTA2022 

Ähnliche Einträge